Chemomab Therapeutics Files Shareholder Meeting Notice
Ticker: CMMB · Form: 6-K · Filed: May 3, 2024 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | May 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, proxy-statement, corporate-governance
Related Tickers: CMMB
TL;DR
Chemomab (CMMB) filed proxy docs for its shareholder meeting. Standard stuff.
AI Summary
Chemomab Therapeutics Ltd. filed a Form 6-K on May 3, 2024, to furnish a Notice and Proxy Statement for its upcoming annual general meeting of shareholders. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is a foreign private issuer based in Tel Aviv, Israel.
Why It Matters
This filing informs shareholders about the upcoming annual general meeting, which is a crucial event for corporate governance and decision-making.
Risk Assessment
Risk Level: low — This is a routine filing providing notice of a shareholder meeting, not indicating any new financial or operational risks.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Registrant
- Anchiano Therapeutics Ltd. (company) — Former Company Name
- BioCancell Ltd. (company) — Former Company Name
- May 3, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being filed to furnish a Notice and Proxy Statement with respect to the Company's annual general meeting of shareholders.
What is the official name of the company filing this report?
The company's name is Chemomab Therapeutics Ltd.
When was this document filed with the SEC?
This document was filed on May 3, 2024.
Has the company undergone name changes in the past?
Yes, the company was formerly known as Anchiano Therapeutics Ltd. (name change on 20180906) and BioCancell Ltd. (name change on 20111104).
Where is Chemomab Therapeutics Ltd. headquartered?
The company's principal executive offices are located at Kiryat Atidim, Building 7, Tel-Aviv, Israel.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-05-03 16:03:07
Filing Documents
- zk2431322.htm (6-K) — 13KB
- exhibit_99-1.htm (EX-99.1) — 151KB
- exhibit_99-2.htm (EX-99.2) — 37KB
- image1.jpg (GRAPHIC) — 332KB
- image3.jpg (GRAPHIC) — 148KB
- 0001178913-24-001564.txt ( ) — 862KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE Chemomab Therapeutics Ltd. (the "Company") hereby furnishes the following documents: (i) Notice and Proxy Statement with respect to the Company's annual general meeting of the shareholders (the "Meeting") to be held on June 10, 2024, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting. (ii) Proxy Card whereby holders of American Depository Shares of the Company may vote at the Meeting without attending in person. This Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868). - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: May 3, 2024 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer - 3 -